• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Report: Increase in Biopharma new product launches originating from in-licensing deals

Report: Increase in Biopharma new product launches originating from in-licensing deals

October 18, 2013
CenterWatch Staff

Decision Resources, a research and advisory firms for pharmaceutical and healthcare issues, reports that biopharma companies industry-wide are increasingly moving away from in-house research and toward acquisitive strategies to build their portfolios and grow sales. According to findings from the Strategic Insights report, the fraction of new product launches that originate from in-licensing has increased dramatically over the last decade. In 2012, 53% of new product launches were in-licensed during development, as compared to an average of 32% between 2003 and 2012.

The report also finds that while 72% of marketed products and pipeline compounds for large pharma companies are sourced in-house or through corporate acquisitions, the corresponding fraction for regional and mid-size companies is only 52%, likely reflecting the latter's reliance on in-licensing of brands for distribution in regional markets. Although company R&D budgets on average have remained constant as a percentage of pharmaceutical sales since 2008, the increasing cost of new product development makes it unlikely that in-house R&D programs can maintain constant levels of productivity.

"As biopharma companies look toward outside partnerships to supplement their pipelines, we see deal-making concentrated in therapeutic areas that are a combination of high sales and high growth, such as oncology," said Patrick Flight, Ph.D., Decision Resources analyst. "Whether the current trend of external sourcing of innovation will remain a viable strategy in an increasingly competitive market for in-licensing and product acquisition opportunities remains to be seen."

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing